TaGRISSO® (osimertinib) plus savolitinib reduced risk of disease progression or death by 45% and risk of death by 32% in MET-preventable lung cancer after progression on TAGRISSO - Company Announces - FT.com.

TaGRISSO® (osimertinib) plus savolitinib reduced risk of disease progression or death by 45% and risk of death by 32% in MET-preventable lung cancer after progression on TAGRISSO - Company Announces - FT.com.